Butler University | 2003 | Pharm.D.
Marc Scheetz attained a Doctorate of Pharmacy from Butler University, earned a Masters of Science in Clinical Investigation degree at Northwestern University, and completed his pharmacy practice residency and an infectious diseases fellowship at Northwestern Memorial Hospital. Dr. Scheetz is a Professor at Midwestern University in the Chicago College of Pharmacy and holds a joint appointment in the Department of Pharmacology, College of Graduate Studies. Dr. Scheetz is the Director of the Pharmacometric Center of Excellence at Midwestern University. He currently practices clinically as an infectious diseases pharmacist at Northwestern Memorial Hospital in downtown Chicago, IL and serves as the Director for the Post-Doctoral Fellowship Program in Infectious Diseases Pharmacotherapy.
Dr. Scheetz has authored a number of original research manuscripts and review articles in the area of anti-infective pharmacokinetics and pharmacodynamics and currently serves as a reviewer for several infectious diseases, pharmacy, and medical journals. His primary research interest lies in the interface of the pharmacokinetic/pharmacodynamic interaction (i.e. between antimicrobials, pathogens, and hosts). He is particularly interested in assessing modifiable pharmacologic variables in the treatment of infectious diseases and identifying optimal exposures against the backdrop of toxicity. His group studies toxicology in the laboratory as well as through clinical data modeling. Dr. Scheetz is actively engaged in local and national leadership positions and formerly served as a member of the FDA Antimicrobial Drugs Advisory Committee.
Downers Grove, IL
Chicago College of Pharmacy
College of Graduate Studies - IL
Butler University | 2003 | Pharm.D.
Select Publications (out of >130 peer reviewed manuscripts)
1: Avedissian SN, Pais GM, O'Donnell JN, Lodise TP, Liu J, Prozialeck WC, Joshi
MD, Lamar PC, Becher L, Gulati A, Hope W, Scheetz MH. Twenty-four hour
pharmacokinetic relationships for intravenous vancomycin and novel urinary
biomarkers of acute kidney injury in a rat model. J Antimicrob Chemother. 2019
Aug 1;74(8):2326-2334. doi: 10.1093/jac/dkz167. PubMed PMID: 31065686; PubMed
Central PMCID: PMC6640290.
2: Pais GM, Avedissian SN, O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC,
Lamar PC, Cluff C, Gulati A, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH.
Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney
Injury According to Timeline of Injury. Antimicrob Agents Chemother. 2019 Jun
24;63(7). pii: e00079-19. doi: 10.1128/AAC.00079-19. Print 2019 Jul. PubMed PMID:
30988153; PubMed Central PMCID: PMC6591602.
3: Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH.
Vancomycin Area under the Curve and Acute Kidney Injury: A Meta-analysis. Clin
Infect Dis. 2019 Feb 1. doi: 10.1093/cid/ciz051. [Epub ahead of print] PubMed
4: Liu J, Kaye KS, Mercuro NJ, Davis SL, Patel TS, Petty LA, Pais GM, Scheetz MH.
It is time to define antimicrobial never events. Infect Control Hosp Epidemiol.
2019 Feb;40(2):206-207. doi: 10.1017/ice.2018.313. Epub 2018 Dec 5. PubMed PMID:
5: Avedissian SN, Rhodes NJ, Liu J, Aljefri D, Postelnick MJ, Sutton SH, Zembower
TR, Martin D, Pais G, Cruce CE, Scheetz MH. Understanding the Components,
Calculation, and Impact of Monthly and Seasonal Variation of the Standardized
Antimicrobial Utilization Ratio (SAAR). Antimicrob Agents Chemother. 2019 Feb
26;63(3). pii: e01780-18. doi: 10.1128/AAC.01780-18. Print 2019 Mar. PubMed PMID:
30602510; PubMed Central PMCID: PMC6395939.
6: Avedissian SN, Pais G, Joshi MD, Rhodes NJ, Scheetz MH. A Translational
Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of
Cefepime. mSphere. 2019 Jan 30;4(1). pii: e00595-18. doi:
10.1128/mSphere.00595-18. PubMed PMID: 30700511; PubMed Central PMCID:
7: Miglis C, Rhodes NJ, Avedissian SN, Kubin CJ, Yin MT, Nelson BC, Pai MP,
Scheetz MH. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult
Patients. Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01475-17. doi:
10.1128/AAC.01475-17. Print 2018 Mar. PubMed PMID: 29311071; PubMed Central
8: Miglis C, Rhodes NJ, Kuti JL, Nicolau DP, Van Wart SA, Scheetz MH. Defining
the impact of severity of illness on time above the MIC threshold for cefepime in
Gram-negative bacteraemia: a 'Goldilocks' window. Int J Antimicrob Agents. 2017
Sep;50(3):487-490. doi: 10.1016/j.ijantimicag.2017.04.023. Epub 2017 Jun 28.
PubMed PMID: 28668683.
9: Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff
C, Lamar PC, Neely MN, Gulati A, Scheetz MH. Evaluation of Vancomycin Exposures
Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in
Vancomycin-Treated Rats. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5742-51.
doi: 10.1128/AAC.00591-16. Print 2016 Oct. Erratum in: Antimicrob Agents
Chemother. 2017 Mar 24;61(4):. PubMed PMID: 27431226; PubMed Central PMCID:
10: Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu J, Lee BJ, Neely
MN, Scheetz MH. Defining Clinical Exposures of Cefepime for Gram-Negative
Bloodstream Infections That Are Associated with Improved Survival. Antimicrob
Agents Chemother. 2015 Dec 14;60(3):1401-10. doi: 10.1128/AAC.01956-15. PubMed
PMID: 26666929; PubMed Central PMCID: PMC4775983.
The following assays have been developed by our group for Research Use Only:
atenolol, azithromycin, cefepime, ceftazidime,colistin, dalbavancin, creatinine, meropenem, micafungin, piperacillin, polymyxin B, sulbactam, tazobactam, vancomycin.
Please contact Dr. Scheetz for more information.